UK bTB Vaccine Programme Completes Major On-Farm Trial Phase
The United Kingdom has reached an important milestone in its long-running effort to develop a practical vaccine against bovine tuberculosis (bTB), with the completion of a major phase of on-farm field trials involving cattle vaccinated with BCG and evaluated using a DIVA (Differentiating Infected from Vaccinated Animals) skin test.
The programme, supported by the Animal and Plant Health Agency (APHA), the UK Government and industry organisations including the National Farmers’ Union (NFU), is considered one of the most significant livestock disease control initiatives currently underway in Europe.
Why Bovine Tuberculosis Remains a Major Challenge
Bovine tuberculosis, caused by Mycobacterium bovis, continues to impose substantial economic and animal welfare costs on the UK cattle industry.
The disease can result in:
-
Reduced cattle productivity
-
Movement restrictions
-
Herd breakdowns
-
Mandatory testing
-
Culling of infected animals
-
Significant financial losses for farmers
Controlling the disease has remained a national priority for many years because of its impact on dairy and beef production.
Why a Vaccine Has Been Difficult to Develop
Unlike many livestock diseases, bovine tuberculosis presents a unique diagnostic challenge.
Traditional skin tests detect the animal’s immune response to tuberculosis bacteria. However, cattle vaccinated with BCG can produce similar immune reactions, making it difficult to distinguish vaccinated animals from naturally infected animals.
To overcome this problem, researchers have been developing the DIVA test, designed to differentiate infected cattle from vaccinated cattle. This diagnostic tool is considered essential before any national vaccination programme can be introduced.
What the Field Trials Are Testing
The recently completed field phase evaluated cattle vaccinated with BCG under commercial farming conditions while also assessing the performance of the accompanying DIVA skin test.
Researchers are examining several key questions, including:
-
Vaccine safety
-
Immune response
-
Diagnostic performance of the DIVA test
-
Practical use under farm conditions
The data collected during these studies will support future regulatory assessment and policy decisions.
A Long-Term Goal for the UK Livestock Industry
The UK Government has previously indicated that, subject to successful scientific evaluation, regulatory approval and international trade considerations, a deployable cattle vaccine could become available around 2030.
However, several important steps remain before widespread vaccination can begin, including:
-
Completion of scientific analysis
-
Regulatory review
-
Validation of diagnostic performance
-
International recognition of vaccinated cattle within trade frameworks
For these reasons, experts caution that completion of the field trials represents an important milestone rather than the final step.
Potential Benefits for Farmers
If successfully licensed and implemented, a cattle vaccine could become an additional tool within broader bovine tuberculosis control programmes.
Potential long-term benefits may include:
-
Reduced disease transmission
-
Improved cattle health
-
Lower economic losses
-
Greater confidence in disease management
-
Better long-term herd resilience
Vaccination is expected to complement, rather than replace, existing surveillance, testing and biosecurity measures.
Why the DIVA Test Matters
The DIVA test is widely regarded as one of the most important innovations within the programme.
Without a reliable test capable of distinguishing vaccinated animals from infected animals, routine tuberculosis surveillance and international cattle trade would become significantly more complicated.
Its successful development is therefore considered just as important as the vaccine itself.
Industry Perspective
The completion of this phase of field trials represents encouraging progress in one of the world’s most ambitious livestock disease research programmes. While further scientific evaluation and regulatory review remain necessary, the combination of BCG vaccination and DIVA diagnostics offers a promising pathway towards improving bovine tuberculosis control without compromising disease surveillance.
For cattle producers, veterinarians and policymakers, the coming years will be critical as researchers analyse trial data and determine whether the programme can meet its goal of making a practical cattle vaccine available around 2030.
Key Highlights
-
The UK bovine tuberculosis vaccine programme has completed a major on-farm field trial phase.
-
Researchers are evaluating BCG vaccination together with a DIVA skin test designed to distinguish vaccinated cattle from infected cattle.
-
Bovine tuberculosis remains one of the UK’s most important livestock diseases, affecting both dairy and beef herds.
-
Additional scientific analysis, regulatory review and international acceptance are required before any national vaccination programme can begin.
-
The UK continues to target a deployable cattle vaccine around 2030, subject to successful completion of the development programme.
